Clinical review for general practice

ISSN (Print) 2713-2552
ISSN (Online) 2782-5671
  • Home
  • about
  • archives
  • contacts
left
FULLSCREEN > Archive > 2024 > Vol 5, №12 (2024) > Cosmetic results of using high-output Ir-192 brachytherapy in the treatment of luminal breast cancer

Cosmetic results of using high-output Ir-192 brachytherapy in the treatment of luminal breast cancer

Marina V. Kiseleva , Andrey D. Kaprin , Sergey A. Ivanov , Igor A. Gulidov , Gamzat G. Aminov , Elena V. Litvyakova , Irina A. Zharikova

For citation:


  • Abstract
  • About the Author
  • References

Abstract

Relevance. Breast cancer is the first most common cancer in women not only in Russia, but also around the world. In Russia in 2021, there were 76 000 women diagnosed with breast cancer. As a result of screening programmes, preventive examinations, and educational work, the detection rate of the disease at stages I–II has reached 72%. This determines the implementation of organ-preserving surgical interventions, but a postoperative course of radiotherapy can significantly worsen the cosmetic result. 
Materials and methods. In our work, we analyzed the cosmetic results in 166 patients who received surgical treatment including lumpectomy for breast cancer with cT1сN0M0 stage. All patients had a luminal, HER2 negative tumor subtype. In accordance with the treatment methods, the main clinical group A (n=80) was formed, which included women who underwent organ-preserving surgical treatment and multifractional high-dose rate brachytherapy with a dose of 1.7 Gy ×2 times a day up to a dose of 34 Gy. Group B (n=86) included patients who underwent organ-preserving surgery and standard radiation therapy with a dose of 2 Gy per day up to a dose of 50 Gy. The groups were comparable in molecular biological characteristics, age and number of patients. 
Results. According to the 4-scale assessment of cosmetic results, it should be noted that after 6 months, “excellent” and “good cosmetic result” was higher in group B and it was 81.4% compared to 62.5% in Group A. This was due to the defects in the area of introducers placement and additional pigmentation in this area. According to our data, at 24 months there was an increase in “satisfactory” results in the group with external beam radiation therapy, which was associated with the occurrence of late radiation injuries, and the group with interstitial radiation therapy has better cosmetic results of 87.5% compared to 77.9%, as well as fewer satisfactory results: 12.5% compared to 22.1%.To receive a subjective assessment from the patients, we used a questionnaire with a 10-point scale. When studying questionnaires, it was noted that in group A, women were more satisfied with the cosmetic results, which was associated not only with a less scope of surgical intevention (lumpectomy versus sectoral resection), which affected the shape of the mammary gland, but also in this group there was less swelling and thickening of the breast skin and changes in the breast tissue itself. 
Conclusions. Brachytherapy in patients with early stages of breast cancer has good cosmetic results, which has a positive effect on the emotional state of women.
Keywords: breast cancer, lumptectomy, Ir-192 brachytherapy, cosmetic result. 

About the Author

Marina V. Kiseleva 1 , Andrey D. Kaprin 2 , Sergey A. Ivanov 3 , Igor A. Gulidov 1 , Gamzat G. Aminov 1 , Elena V. Litvyakova 1 , Irina A. Zharikova 1

1 Tsyb Medical Radiological Research Centre – branch of the National Medical Research Radiological Centre, Obninsk, Russia

2 National Medical Research Radiological Centre, Moscow, Russia; Herzen Moscow Oncology Research Institute – branch of the National Medical Research Radiological Centre, Moscow, Russia

3 Tsyb Medical Radiological Research Centre – branch of the National Medical Research Radiological Centre, Obninsk, Russia; Patrice Lumumba People’s Friendship University of Russia (RUDN University), Moscow, Russia

References

1. Злокачественные новообразования в России в 2023 году (заболеваемость и смертность). Под ред. А.Д. Каприна и др. М.: МНИОИ им. П.А. Герцена − филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2024. ISBN 978-5-85502-298-8
Malignant neoplasms in Russia in 2023 (morbidity and mortality). Ed. A.D. Kaprin et al. Moscow: Herzen Moscow Oncology Research Institute – branch of National Medical Research Center for Radiology, 2024. ISBN 978-5-85502-298-8 (in Russian).
2. Рак молочной железы в цифрах: эпидемиология, диаграммы, видео. Информационно-аналитическое издание «Вместе против рака» 1 июня 2022 года. URL: https://protiv-raka.ru/analytics/epidemiologiya-rmzh-v-interaktivnyh-diagrammah/
Breast cancer in numbers: epidemiology, diagrams, videos. Information and analytical publication «Together against cancer» on June 1, 2022. URL: https://protiv-raka.ru/analytics/epidemiologiya-rmzh-v-interaktivnyh-diagrammah/ (in Russian).
3. Vaidya JS, Joseph DJ, Tobias JS et al. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomized, non-inferiority phase 3 trial. Lancet 2010;376(9735):91-102.
4. Fisher B, Anderson S, Bryant J et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 2002;347(16):1233-41.
5. Pawlik TM, Buchholz TA, Kuerer HM. The biologic rational for and emerging role of accelerated partial breast irradiation for breast cancer. J Am Coll Surg 2004;199(3):479-92.
6. Schroen AT, Brenin DR, Kelly MD et al. Impact of patient distance to radiation therapy on mastectomy use in early-stage breast cancer patients. J Clin Oncol 2005;23(28):7074-80.
7. Вершинина Д.А., Семиглазов В.В., Новиков С.Н. Повышение эффективности послеоперационной лучевой терапии раннего рака молочной железы. Эффективная фармакотерапия. 2020;16(11): 32–41.
Vershinina D.A., Semiglazov V.V., Novikov S.N. Improving the effectiveness of postoperative radiation therapy for early breast cancer. Effective pharmacotherapy. 2020;16(11):32–41 (in Russian).
8. Хмелевский Е.В., Добренький М.Н., Сергоманова Н.Н. и др. Факторы риска постлучевых поражений при заболевании раком молочной железы. Вестник Российского научного центр рентгенорадиологии №5 Москва. URL: http://vestnik.rncrr.ru/vestnik/v5/papers/hmel_v5.htm
Khmelevsky E.V., Dobrenky M.N., Sergomanova N.N. et al. Risk factors for post-radiation lesions in breast cancer. Bulletin of the Russian Scientific Center of Radiology No.5 Moscow. URL: http://vestnik. rncrr.ru/vestnik/v5/papers/hmel_v5.htm (in Russian).
9. Бинд П., Росфорс С., Веннберг Б. и др. Функция легких после адъювантной химиотерапии и лучевой терапии рака молочной железы и вопросы трехмерного планирования лечения. Radiother Oncol. 1998;49:245-54.
Band P., Rosfors S., Weinberg B. et al. Lung function after adjuvant chemotherapy and radiation therapy for breast cancer and issues of three-dimensional treatment planning. Radiother Oncol. 1998;49:245-54 (in Russian).
10. Arthur DW, Winter K, Kuske RR et al. A Phase II trial of brachytherapy alone after lumpectomy for select breast cancer: tumor control and survival outcomes of RTOG 95-17. Int J Radiat Oncol Biol Phys 2008;72:467-47.
11. Cormick B. A Phase II trial of brachytherapy alone after lumpectomy for select breast cancer: tumor control and survival outcomes of RTOG 95-17. Int J Radiat Oncol Biol Phys 2008;72:467-47.
12. Masuda N et al. Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial. Lancet Oncol 2012;13(4):345-52. DOI: 10.1016/S1470-2045(11)70373-4
13. Latorre, Javier Anchuelo; Galdós et al. Accelerated partial breast irradiation in a single 18 Gy fraction with high-dose-rate brachytherapy: preliminary results. Journal of Contemporary Brachytherapy 2018;10(1):58-63.
14. Vicini FA, Beitsch PD, Quiet CA et al. Three-year analysis of efficacy, cosmetic, and toxicity by the American Society of Breast Surgeons MammoSite breast brachytherapy registry trial in patients with accelerated partial breast irradiation (APBI). Cancer 2008;112(4):758-66.
15. Wishart, Gordon et al. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5- year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. The Lancet. Online First – In Press, Corrected Proof, 2017.
16. Polgár C, Ott OJ, Hildebrandt G et al; Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO).
17. Wazer DE, Kaufman S, Cuttino L et al. Accelerated partial breast irradiation: an analysis of variables associated with late toxicity and long-term cosmetic outcome after high-dose-rate interstitial brachytherapy. Int J Radiat Oncol Biol Phys 2006;64(2):489-95.
18. Radiation Therapy Oncology Group National Surgical Adjuvant Breast and Bowel Project (NSABP) protocol B-39 and Radiation Therapy Oncology Group (RTOG) protocol 0413. 2005. Mar. Accessed Oct 22, 2010.

For citation:Kiseleva M.V., Kaprin А.D., Ivanov S.А., Gulidov I.A., Aminov G.G., Litviakova E.V., Zharikova I.A. Cosmetic results of using high-output Ir-192 brachytherapy in the treatment of luminal breast cancer. Clinical review for general practice. 2024; 5 (12): 10–16 (In Russ.). DOI: 10.47407/kr2024.5.12.00531


All accepted articles publish licensed under a Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.

  • About
  • Editorial board
  • Ethics
  • For authors
  • Author fees
  • Peer review
  • Contacts

oa
crossref
анри


  Indexing

doaj
elibrary

Address of the Editorial Office:

127055, Moscow, s/m 37

Correspondence address:

115054, Moscow, Zhukov passage, 19, fl. 2, room XI


Managing Editor:

+7 (495) 926-29-83

id@con-med.ru